Myeloma2018 Session V

 

Progression of MGUS-SMM-MM

Session V of Myeloma2018 saw experts Jose Martinez-Climent, MD, Celine Vachon, PhD, Niels Weinhold, PhD, and Elisabet Manasanch, MD, speak on the pathobiological and clinical aspects of the development of multiple myeloma, from monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM). The stimulating presentations in this session focus on mouse modelling, the prognostic molecular techniques, and genetic mechanisms associated with predisposition to MM.

Presentations
Modeling MM Development in Mice
Jose Martinez-Climent, MD
University of Navarra, Pamplona, Spain
8 September, 2018

Jose Martinez-Climent, MD, from the University of Navarra, Pamplona, Spain, explores modelling MM development in mice models.

Genetic Predisposition to Multiple Myeloma
Celine Vachon, PhD
Mayo Clinic, Rochester, MN
8 September, 2018

Celine Vachon, PhD, from the Mayo Clinic, Rochester, MN, speaks on genetic predispositions to myeloma.

Single Cell Analyses in MGUS and SMM
Niels Weinhold, PhD
UAMS Myeloma Institute, Little Rock, AR
8 September, 2018

Niels Weinhold, PhD, from the UAMS Myeloma Institute, Little Rock, AR, talks about single cell sequencing in MGUS and SMM.

Clinical Insights in the Progression to Multiple Myeloma
Elisabet Manasanch, MD
MD Anderson Cancer Center, Houston, TX
8 September, 2018

Elisabet Manasanch, MD, from the MD Anderson Cancer Center, Houston, TX, discusses clinical insights in MM progression.